North America Smoking Cessation and Nicotine De-Addictions Market, By Product Type (With Nicotine and Without Nicotine), Treatment Type (Pharmacological, Therapies and Others) Distribution Channel (Online, Offline), End-User (Generation Z, Millennials, Generation X and Silent Generation) – Industry Trends and Forecast to 2029
Market Analysis and Size
The number of people addicted to smoking is rapidly growing all over the world. This population subset consists primarily of teenagers and the working population. The mortality rate from smoking is extremely high. The growing desire to quit smoking and the numerous health risks associated with smoking provide strong incentives for companies to develop novel smoking cessation products.
Data Bridge Market Research analyses that the smoking cessation and nicotine de-addictions market was valued at USD 38.58 billion in 2021 and is expected to reach the value of USD 221.27 billion by 2029, at a CAGR of 24.4% during the forecast period of 2022 to 2029.
Market Definition
Tobacco withdrawal is part of smoking cessation or nicotine de-addiction. Tobacco contains nicotine, which is known to cause addiction by releasing neurotransmitters such as dopamine, gamma-aminobutyric acid (GABA), and glutamate. Smoking cessation aids in the treatment of cigarette and tobacco addicts.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product Type (With Nicotine and Without Nicotine), Treatment Type (Pharmacological, Therapies and Others) Distribution Channel (Online, Offline), End-User (Generation Z, Millennials, Generation X and Silent Generation)
|
|
Countries Covered
|
U.S., Canada and Mexico
|
|
Market Players Covered
|
Imperial Brands (UK), 22nd Century Group, Inc (U.S), Pfizer Inc. (U.S). Dr. Reddy’s Laboratories Ltd (India), Glaxosmithkline Plc. (UK), British American Tobacco (UK), Cambrex Corporation (U.S), Cipla Inc. (U.S), Fertin Pharma (Denmark), Johnson & Johnson private limited (U.S), Perrigo Company Plc (Ireland)
|
|
Opportunities
|
|
Smoking Cessation and Nicotine De-Addictions Market Dynamics
Drivers
- Rise in the number of people attempting to quit smoking around the world
One of the major factors driving the growth of the smoking cessation and nicotine de-addiction market is the increase in the number of people attempting to quit smoking around the world. Due to the toxic effects of nicotine and cigarette addiction on the cardiac and respiratory systems, the government emphasizes strict regulations to control nicotine and cigarette addiction, and high taxes on tobacco products accelerate market growth. Furthermore, high adoption of unhealthy lifestyle options, rapid urbanization, and an increase in disposable income all benefit the smoking cessation and nicotine de-addiction market.
- Strict regulations laid down by government to control nicotine and cigarette addiction
The government is emphasising strict regulations to control nicotine and cigarette addiction due to the toxic effects on the cardiac and respiratory systems. Smoking bans in public places, high taxes on tobacco products, and financial support for smoking cessation therapies are examples of government smoking cessation policies. As a result, during the forecast period, the global market for smoking cessation and nicotine de-addiction products is expected to grow rapidly.
Opportunities
The introduction of improved and innovative nicotine replacement therapy products is expected to be a significant driving force in the growth of the smoking cessation and nicotine de-addiction market. The rising prevalence of target diseases such as chronic obstructive pulmonary disease (COPD), asthma, cardiac diseases, and lung cancer, as well as growing public awareness of the dangers of smoking, are expected to drive market growth. An educational institution continue to be active in organising various campaigns and programmes to spread information about the harmful effects and consequences of smoking in order to raise the awareness of the young population.
Restraints
Reluctance to accept the treatment, on the other hand, is expected to stymie market growth. The smoking cessation and nicotine de-addiction market is expected to face challenges due to a lack of awareness in the forecast period.
This smoking cessation and nicotine de-addictions market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the smoking cessation and nicotine de-addictions market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Smoking Cessation and Nicotine De-Addictions Market
COVID-19 diagnosis was five times more likely among e-cigarette users alone, but it is also associated with the dual risk of e-cigarettes and cigarettes, implying that e-cigarettes may be underlying risk factors for COVID-19. Tobacco use increases the risk of infection, the likelihood of complications, and the likelihood of disease spread. Only 30% of users reported that the current situation had influenced their tobacco use, with the most common consequences being a lack of tobacco products and higher prices. During the lockdown, 34% of tobacco users in the population studied quit smoking. 51 percent of those who left did so due to the lockdown and their concerns about COVID-19. As a result, the COVID-19 pandemic had a significant impact on the smoking cessation aids market.
Recent Development
- JB Chemicals & Pharmaceuticals will introduce medicated nicotine lozenges in May 2021 to help reduce the desire to consume or smoke tobacco.
- NFL Biosciences SA, a biopharmaceutical company developing botanical drugs for the treatment of addictions, will begin its CESTO II Phase II/III clinical trial in December 2021 to evaluate the efficacy and safety of its NFL-101 smoking cessation treatment.
North America Smoking Cessation and Nicotine De-Addictions Market Scope
The smoking cessation and nicotine de-addictions market is segmented on the basis of product type, treatment type, distribution channel and end-use. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product Type
- With Nicotine
- Without Nicotine
Treatment type
- Pharmacological
- Therapies
- Others
Distribution channels
- Online
- Offline
End user
- Generation Z
- Millennials
- Generation X
- Silent Generation
Smoking Cessation and Nicotine De-Addictions Market Regional Analysis/Insights
The smoking cessation and nicotine de-addictions market is analyzed and market size insights and trends are provided by country, product type, treatment type, distribution channel and end-user as referenced above.
The countries covered in the smoking cessation and nicotine de-addictions market report are U.S., Canada and Mexico.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Smoking Cessation and Nicotine De-Addictions Market Share Analysis
The smoking cessation and nicotine de-addictions market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, North America presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to smoking cessation and nicotine de-addictions market.
Some of the major players operating in the smoking cessation and nicotine de-addictions market are:
- Imperial Brands (UK)
- 22nd Century Group, Inc (U.S)
- Pfizer Inc. (U.S)
- Dr. Reddy’s Laboratories Ltd (India)
- Glaxosmithkline Plc. (UK)
- British American Tobacco (UK)
- Cambrex Corporation (U.S)
- Cipla Inc. (U.S)
- Fertin Pharma (Denmark)
- Johnson & Johnson private limited (U.S)
- Perrigo Company Plc (Ireland)
SKU-